Patient and disease characteristics
| N | 45 |
| Median age, y (range) | 49 (20-68) |
| Sex, male/female | 28/17 |
| Median no. of prior therapies (range) | 2 (0-5) |
| Median follow-up, d (range) | 372 (24-820) |
| Prior ABMT | 26 |
| CMV status neg/neg | 0 |
| Thiotepa mg/kg, 15/10/5 | 14/24/7 |
| Stem cell source | |
| marrow | 17 |
| PBPC | 28 |
| Median CD 34+ × 10e6/kg, BM/PBPC | 3.8/5.7 |
| Donor type | |
| 6 of 6 matched related | 42 |
| 5 of 6 mismatched related | 3 |
| Diagnosis and status at transplantation | |
| AML/RAEB-t/ALL | 5/6/1 |
| CR1 | 3 |
| ≥CR2 | 2 |
| Untreated | 4 |
| Refractory | 3 |
| Indolent/high-grade lymphoma | 13/11 |
| CR1 | 1 |
| PR | 6 |
| ≥CR2 | 4 |
| Refractory | 9 |
| Hodgkin disease/multiple myeloma | 4/5 |
| CR1 | 0 |
| PR | 2 |
| ≥CR2 | 0 |
| Untreated relapse | 1 |
| Refractory | 6 |
| N | 45 |
| Median age, y (range) | 49 (20-68) |
| Sex, male/female | 28/17 |
| Median no. of prior therapies (range) | 2 (0-5) |
| Median follow-up, d (range) | 372 (24-820) |
| Prior ABMT | 26 |
| CMV status neg/neg | 0 |
| Thiotepa mg/kg, 15/10/5 | 14/24/7 |
| Stem cell source | |
| marrow | 17 |
| PBPC | 28 |
| Median CD 34+ × 10e6/kg, BM/PBPC | 3.8/5.7 |
| Donor type | |
| 6 of 6 matched related | 42 |
| 5 of 6 mismatched related | 3 |
| Diagnosis and status at transplantation | |
| AML/RAEB-t/ALL | 5/6/1 |
| CR1 | 3 |
| ≥CR2 | 2 |
| Untreated | 4 |
| Refractory | 3 |
| Indolent/high-grade lymphoma | 13/11 |
| CR1 | 1 |
| PR | 6 |
| ≥CR2 | 4 |
| Refractory | 9 |
| Hodgkin disease/multiple myeloma | 4/5 |
| CR1 | 0 |
| PR | 2 |
| ≥CR2 | 0 |
| Untreated relapse | 1 |
| Refractory | 6 |
ABMT indicates autologous bone marrow transplantation; CMV, cytomegalovirus; PBPC, mobilized peripheral blood cells; BM, marrow cells; AML, acute myelogenous leukemia; RAEB-t, refractory anemia with excess of blasts in transformation; ALL, acute lymphocytic leukemia; CR, complete remission; and PR, partial remission.